Machine learning for subtype definition and risk prediction in heart failure, acute coronary syndromes and atrial fibrillation: systematic review of validity and clinical utility
Year: 2021
Type: review
Study design: Systematic Review
Abstract: BACKGROUND: Machine learning (ML) is increasingly used in research for subtype definition and risk prediction, particularly in cardiovascular diseases. No existing ML models are routinely used for cardiovascular disease management, and their phase of clinical utility is unknown, partly due to a lack of clear criteria. We evaluated ML for subtype definition and risk prediction in heart failure (HF), acute coronary syndromes (ACS) and atrial fibrillation (AF). METHODS: For ML studies of subtype definition and risk prediction, we conducted a systematic review in HF, ACS and AF, using PubMed, MEDLINE and Web of Science from January 2000 until December 2019. By adapting published criteria for diagnostic and prognostic studies, we developed a seven-domain, ML-specific checklist. RESULTS: Of 5918 studies identified, 97 were included. Across studies for subtype definition (n = 40) and risk prediction (n = 57), there was variation in data source, population size (median 606 and median 6769), clinical setting (outpatient, inpatient, different departments), number of covariates (median 19 and median 48) and ML methods. All studies were single disease, most were North American (n = 61/97) and only 14 studies combined definition and risk prediction. Subtype definition and risk prediction studies respectively had limitations in development (e.g. 15.0% and 78.9% of studies related to patient benefit; 15.0% and 15.8% had low patient selection bias), validation (12.5% and 5.3% externally validated) and impact (32.5% and 91.2% improved outcome prediction; no effectiveness or cost-effectiveness evaluations). CONCLUSIONS: Studies of ML in HF, ACS and AF are limited by number and type of included covariates, ML methods, population size, country, clinical setting and focus on single diseases, not overlap or multimorbidity. Clinical utility and implementation rely on improvements in development, validation and impact, facilitated by simple checklists. We provide clear steps prior to safe implementation of machine learning in clinical practice for cardiovascular diseases and other disease areas.
Source: BMC Medicine
Institutions: University College London Hospitals NHS Foundation Trust, Barts Health NHS Trust, Royal London Hospital, Health Data Research UK, University College London, King's College London, Bayer (Germany), University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, University Medical Center Utrecht, The Alan Turing Institute, UCL Biomedical Research Centre
Language: English
Subfield: Health Information Management
Field: Health Professions
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,580
Awards: G1175529158, Centre for Health service and Academic Partnership in Translational eHealth Research (CHAPTER), Centre for Health service and Academic Partnership in Translational eHealth Research (CHAPTER), G4547791843, 'Unlocking therapeutic innovation in heart failure through genomic data science, Accelerator Award (round 1), Preventing stroke, premature death and cognitive decline in a broader community of patients with atrial fibrillation using healthcare data for pragmatic research (DaRe2THINK), Optimising rate-control therapy in older patients with AF – a training fellowship and pilot study focused on improving quality of life, Cardiotonic steroids in patients with atrial fibrillation and heart failure: Quantification, functional effects and personalisation of digoxin therapy
OpenAlex ID: W3145086671
